Correction to: Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients

Eitemau Tebyg

• Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients
  gan: Tsuruya, Kazuhiko, et al.
  Cyhoeddwyd: (2019)
• Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
  gan: Yokoyama, Keitaro, et al.
  Cyhoeddwyd: (2019)
• Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
  gan: Shigematsu, Takashi, et al.
  Cyhoeddwyd: (2018)
• Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
  gan: Akizawa, Tadao, et al.
  Cyhoeddwyd: (2018)
• Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”
  gan: Akizawa, Tadao, et al.
  Cyhoeddwyd: (2019)